Menu Search
Equities

Carl Zeiss Meditec AG

AFX:HAN

Carl Zeiss Meditec AG

Actions
  • Price (EUR)54.60
  • Today's Change0.00 / 0.00%
  • Shares traded60.00
  • 1 Year change-36.08%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.

  • Revenue in EUR (TTM)2.07bn
  • Net income in EUR203.20m
  • Incorporated1995
  • Employees4.95k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		AFXX:GER since
announced		Transaction
value
DORC Dutch Ophthalmic Research Center (International) BVDeal completed15 Dec 202315 Dec 2023Deal completed-43.33%1.08bn
Data delayed at least 15 minutes, as of Nov 22 2024 16:35 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.